CAMBRIDGE, Mass. – December 15, 2021 – Repertoire Immune Medicines, Inc. today announced the appointment of B. Lynne Parshall to its Board of Directors. Ms. Parshall is a biotechnology veteran with broad strategic, financial and operational experience at both the senior executive and board levels.

“We welcome Lynne to the Repertoire Board of Directors. Her experience as a senior executive and as an advisor to biotechnology companies during pivotal moments of their growth will be a significant asset as we evolve as an organization,” said John Cox, Chief Executive Officer, Repertoire Immune Medicines. “Lynne’s specialized experience related to the development of novel platform technologies will also benefit our team as we work toward advancing our immune medicines through clinical development.”

During her nearly 30-year career at Ionis Pharmaceuticals, Inc., Ms. Parshall held several executive roles, including chief financial officer and chief operating officer. In this capacity, Ms. Parshall had oversight of all business functions, including regulatory, quality and manufacturing. Her executive positions also included general counsel and she was a member of the Research and Development Management Committees. Ms. Parshall was also responsible for designing and implementing strategic plans to support Ionis’ growth from IPO to a multibillion-dollar market cap.

Ms. Parshall currently serves on the Board of Directors of Ionis and on the Board of Directors of Cytokinetics, Inc. She was a member of the Board of Directors of Akcea Therapeutics, Inc. from 2015 to 2021, serving as chair from 2019 to 2021, until its acquisition by Ionis.

“Lynne brings a history of experience supporting companies at various stages of growth and helping them to navigate business challenges. In addition, she has served in leadership and advisory roles at organizations responsible for bringing groundbreaking and life-saving medicines to patients,” said Doug Cole, M.D., Chairman, Repertoire Immune Medicines’ Board of Directors and Managing Partner, Flagship Pioneering. “She is a terrific addition to the exceptional leaders who are members of our Board of Directors.”

“I am energized by companies that are pushing past the boundaries of existing treatment approaches with the goal of discovering new ways to treat disease,” said Ms. Parshall. “The combination of novel science and great potential is what I find compelling about Repertoire. I look forward to supporting its continued growth and sharing what I have learned through my work in the healthcare industry.”

Prior to joining Ionis, Ms. Parshall practiced law at Cooley LLP, and was a partner from 1987 to 1991. She is a member of the American and California Bar Associations. Ms. Parshall graduated magna cum laude from Harvard University with her bachelor’s degree and received her Juris Doctor from Stanford Law School.

About Repertoire Immune Medicines

Repertoire Immune Medicines is dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens and regulate immune function.

Repertoire’s strategy lies in understanding the immune synapse – the interaction between specific T cells and the corresponding antigen-presenting cells that dictate T cell activity. The company’s proprietary DECODE™ technology platform, developed by Repertoire scientists, provides a comprehensive understanding of the full repertoire of interactions between T cell receptors and their antigen targets. We believe the ability to decode these interactions represents one of the greatest opportunities for innovation in medical science.

Repertoire’s team of more than 160 operates from sites in Cambridge, Massachusetts and Zurich, Switzerland and uses its DECODE technology to rationally design treatments for cancers, autoimmune disorders and infectious diseases.

To learn more about Repertoire, please visit our website: www.repertoire.com and follow us on LinkedIn and Twitter.